Resources
Publications
Download
-
Xarelto Prescriber Guide
26/04/2012 -
DVT Treatment Dosing Card
26/04/2012 -
SPAF Dosing Card
26/04/2012
Xarelto News
- Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots
- Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE
- Bayer’s Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study
Other Websites of Interest
-
New England Journal of Medicine - Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding.
-
New England Journal of Medicine - Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles.
-
ThrombosisManagement CME on TheHeart.org
ThrombosisManagement is a Continuing Medical Education (CME) programme on theheart.org with regular updates.
Benefit Calculator
Events Calendar
For the Press
Go to the Press Resources page to find more information on Xarelto
